Treatment
Share your love
Beacon Therapeutics Initiates VISTA Trial for X-Linked RP
Beacon Therapeutics announced the treatment of the inaugural patient in its pivotal VISTA clinical trial with its lead asset, AGTC-501 (laruparetigene zovaparvovec), marking a significant advancement in the pursuit of combating X-Linked Retinitis Pigmentosa (XLRP). Objective of the VISTA Trial…
Robot Radiotherapy Could Improve Treatment for AMD
Researchers from King’s College London, in collaboration with doctors at King’s College Hospital NHS Foundation Trust, have achieved a breakthrough in treating a debilitating eye disease using a new robot system. This system targets wet neovascular age-related macular degeneration (AMD)…
Melatonin Use Linked to Reduced Risk of AMD
A recent study published online in JAMA Ophthalmology suggests that melatonin use is associated with a decreased risk of both the development and progression of age-related macular degeneration (AMD). Investigating the Association: A Retrospective Cohort Study Hejin Jeong, from the…
Skye Bioscience’s Next Steps After Glaucoma Trial Disappointment
Skye Bioscience’s phase 2a clinical trial of its SBI-100 ophthalmic emulsion in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) has failed to meet its primary endpoint for lowering intraocular pressure (IOP). Consequently, the company announced its decision…
CAM360 AmnioGraft: BioTissue’s Ocular Surface Therapy
BioTissue announced the launch of CAM360 AmnioGraft (CAM360 AG), a new, hydrated, shelf-stable ‘Cryopreserved Amniotic Membrane’ (CAM) solution designed for treating dry eye and various ocular surface disorders. Initial shipments of the product have commenced, with nationwide availability expected by…
Harrow Reveals 52-Week Data for Vevye ESSENCE-2 Study
Harrow, a leading pharmaceutical company, has revealed the encouraging results from its ESSENCE‑2 open-label extension (OLE) clinical study for Vevye (cyclosporine ophthalmic solution) 0.1%, a novel treatment for dry eye disease (DED). Study Design and Outcomes: ESSENCE-2 OLE Analysis The…
Italy Probes Pharma Giants for Market Manipulation
Italy’s antitrust regulator has initiated a probe into several pharmaceutical giants, including Novartis, amid suspicions of anti-competitive practices in the sale of a drug targeting eye conditions. The investigation follows concerns regarding potential market restrictions and delayed product launch of…
Eversight Partners with LighTopTech to Improve Eye Imaging
Eversight has partnered up with LighTopTech to elevate the standards of imaging modalities for eye tissues. This ambitious partnership, spanning over four years, sets out to redefine the landscape of ocular imaging in both clinical and research domains. LighTopTech’s OCX…
CorneaGen Launches CTAK for Keratoconus Patients
CorneaGen, a leading provider of ocular tissue, announced the commercial launch of Corneal Tissue Addition for Keratoplasty (CTAK), a novel solution for corneal contouring in keratoconic eyes. Developed in collaboration with CTAK LLC and Ziemer, CTAK offers patient-ready, gamma-irradiated sterile…
BIOPHTA Secures €6.5M to Advance Eye Disease Therapy
BIOPHTA, a preclinical biotech company, has successfully closed a Seed round, raising €6.5 million to advance its pioneering technology into clinical development for the treatment of glaucoma and macular edema. This significant funding injection, led by prominent European venture capital…